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The development of neuroprotective strategies to attenuate retinal ganglion cell death could lead to novel therapies for chronic
optic neuropathies such as glaucoma. Intravitreal transplantation of mesenchymal stem cells slows retinal ganglion cell death in
models of optic nerve injury, but the mechanism of action remains unclear. Here we characterized the neuroprotective effects of
mesenchymal stem cells and mesenchymal stem cell-derived factors in organotypic retinal explant culture and an in vivo model
of ocular hypertensive glaucoma. Co-culture of rat and human bone marrow-derived mesenchymal stem cells with retinal
explants increased retinal ganglion cell survival, after 7 days ex vivo, by 2-fold and was associated with reduced apoptosis
and increased nerve fibre layer and inner plexiform layer thicknesses. These effects were not demonstrated by co-culture with
human or mouse fibroblasts. Conditioned media from mesenchymal stem cells conferred neuroprotection, suggesting that the
neuroprotection is mediated, at least partly, by secreted factors. We compared the concentrations of 29 factors in human
mesenchymal stem cell and fibroblast conditioned media, and identified 11 enriched in the mesenchymal stem cell secretome.
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Treatment of retinal explants with a cocktail of these factors conferred retinal ganglion cell neuroprotection, with factors from
the platelet-derived growth factor family being the most potent. Blockade of platelet-derived growth factor signalling with
neutralizing antibody or with small molecule inhibitors of platelet-derived growth factor receptor kinase or downstream phos-
phatidylinositol 3 kinase eliminated retinal ganglion cell neuroprotection conferred by mesenchymal stem cell co-culture.
Intravitreal injection of platelet-derived growth factor -AA or -AB led to profound optic nerve neuroprotection in vivo following
experimental induction of elevated intraocular pressure. These data demonstrate that mesenchymal stem cells secrete a number
of neuroprotective proteins and suggest that platelet-derived growth factor secretion in particular may play an important role
in mesenchymal stem cell-mediated retinal ganglion cell neuroprotection. Furthermore, platelet-derived growth factor may
represent an independent target for achieving retinal ganglion cell neuroprotection.
Keywords: mesenchymal stem cell; retinal ganglion cell; neuroprotection; glaucoma; platelet derived growth factor
Abbreviations: DMEM = Dulbecco’s modified Eagle medium; IL = interleukin; MSC = mesenchymal stem cell;
PDGF = platelet-derived growth factor; PEDF = pigment epithelium-derived factor; RGC = retinal ganglion cell; TUNEL = terminal
deoxynucleotidyl transferase dUTP nick end labelling
Introduction
Progressive retinal ganglion cell (RGC) death and optic nerve
damage characterize glaucoma, a neurodegenerative disease for
which the only available treatment is pharmacological or surgical
reduction of intraocular pressure (Quigley, 2011). There is growing
interest in the development of neuroprotective therapies for glau-
coma, which might be used adjunctively with ocular hypotensive
approaches to reduce RGC death and attenuate loss of vision
more effectively (Casson et al., 2012; Chang and Goldberg,
2012). Previously investigated neuroprotective strategies
include neurotrophic factor delivery, molecular suppression of
pro-apoptotic signalling cascades, reduction of oxidative stress,
and suppression of inflammation (reviewed in Danesh-Meyer,
2011; Vasudevan et al., 2011; Almasieh et al., 2012; Chang
and Goldberg, 2012).
While early enthusiasm for the translational prospects of stem
cell research in glaucoma focused on optic nerve regeneration,
neuroprotective properties of various stem cell types are increas-
ingly being appreciated (Bull et al., 2008; Johnson and Martin,
2013). Mesenchymal stem cells (MSCs) are multipotent, with
the ability to differentiate into adipocytes, osteoblasts, chondro-
cytes and myoblasts. In vivo, they are thought to play a role in
maintaining the haematopoietic stem cell niche. MSCs possess
immunomodulatory, antioxidant and neurotrophic characteristics
that support neuronal survival when transplanted to ectopic sites
of degenerative CNS stress (Kassis et al., 2011; Uccelli et al.,
2011). These cells can be readily isolated from bone marrow
aspirates from individual patients and expanded in vitro before
autologous transplantation. For these reasons, MSC transplant-
ation is presently being trialled as a therapy for multiple sclerosis,
ischaemic stroke, spinal cord injury, Parkinson’s disease, and other
conditions (clinicaltrials.gov). In preclinical models of optic nerve
neurodegeneration, MSC transplantation also appears to attenuate
neuronal death. RGC neuroprotection has been noted with local
MSC transplantation following ischaemia/reperfusion (Li et al.,
2009), optic nerve crush (Zhao et al., 2011), optic tract transec-
tion (Zwart et al., 2009), and ocular hypertension induced by
episcleral vein ligation (Yu et al., 2006) or photocoagulation of
the trabecular meshwork (Johnson et al., 2010). Although in-
creases in retinal concentrations of a variety of trophic factors
have been noted after MSC transplantation, the mechanism(s)
by which MSCs confer neuroprotection to RGCs remains unclear.
In this work, we employed in vitro organotypic retinal explant
culture and in vivo experimental ocular hypertension as models
to assess the effects of MSC co-culture and MSC-derived factors
on RGC survival. In doing so, we demonstrated that both rat and
human MSCs exhibited robust neuroprotective properties, and
identified platelet-derived growth factor (PDGF) as a particularly
potent neuroprotective MSC-derived protein, which may explain
much of the neuroprotective effect of these cells.
Materials and methods
Animals
Adult (8–12 week old) Sprague Dawley rats were maintained in
accordance with guidelines set forth by the National Eye Institute
Committee on the Use and Care of Animals, the UK Home Office
regulations for the care and use of laboratory animals, the UK
Animals (Scientific Procedures) Act (1986), and the Association for
Research in Vision and Ophthalmology’s Statement for the Use of
Animals in Ophthalmic and Visual Research.
Cell cultures
Rat MSCs were isolated from the femurs of 8-week-old transgenic
Sprague Dawley rats engineered to express green fluorescent protein
(GFP) under control of the chicken b-actin promoter (Okabe et al.,
1997; Hunt et al., 2008). Femurs were obtained from euthanized rats
and bone marrow was isolated by flushing the femurs with 1–2 ml of
PBS. Mononuclear cells were plated at a density of 5  105 cells/cm2
on plastic culture flasks in Dulbecco’s modified Eagle medium (DMEM;
1 g/l glucose) containing 10% foetal bovine serum, penicillin (100 U/
ml) and streptomycin (100 mg/ml; all from Life Technologies). Non-
adherent cells were removed by complete media exchange after
48 h, and then cells were cultured until 80% confluent before passage.
Rat MSCs used in this study were from passages 12–20.
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Human MSCs were purchased from Stem Cell Technologies and
cultured in DMEM (1 g/l glucose) containing 10% foetal bovine
serum, penicillin and streptomycin. The vendor verified 490% expres-
sion of CD29, CD44, CD105, and CD166 and 51% expression of
CD14, CD34 and CD45 by flow cytometry. Human MSCs were pas-
saged at 80% confluence. Cells used in this study were from passages
5–10. Human adult dermal fibroblasts were purchased from Life
Technologies and cultured in Medium 106 with low serum growth
supplement (both from Life Technologies). Fibroblasts were passaged
at 80% confluence and used in this study at passages 5–10. The
mouse embryonic fibroblast cell line NIH-3T3 (Jainchill et al., 1969)
was cultured in DMEM (4.5 g/l glucose) containing 10% foetal bovine
serum, penicillin and streptomycin. Cells were passaged at 80%
confluence.
The multipotencies of rat and human MSC cultures were verified
experimentally by induction of differentiation into adipocytes and
osteoblasts. This was accomplished by cell culture in StemPro osteo-
genesis or adipogenesis differentiation media according to vendor
instructions (Life Technologies).
Flow cytometry
Live rat MSCs in single-cell suspension were blocked using 1% foe-
tal bovine serum in PBS and then stained immunocytochemically
for surface markers using the following antibodies: hamster anti-
CD29 (1:100, Serotec), mouse anti-CD44 (1:50, Serotec), mouse
anti-CD73 (BD Biosciences), PE-conjugated mouse anti-CD90
(1:50, BD Biosciences), mouse anti-CD34 (1:50, Santa Cruz
Biotechnology Inc.), mouse anti-CD45 (1:100, Serotec), mouse anti-
CD11b (1:50, Serotec), and mouse anti-CD68 (1:100, EMD Millipore).
Secondary Alexa Fluor 647-conjugated goat anti-hamster IgG
or Alexa Fluor 633-conjugated goat anti-mouse IgG (Life
Technologies) were used where appropriate. Negative controls
included cells with primary antibody omitted from the staining proto-
col. Analyses were carried out using a FACSCalibur flow cytometer
(BD biosciences).
Organotypical retinal explant culture
Primary organotypical retinal explants were isolated and cultured as
previously described (Johnson and Martin, 2008; Bull et al., 2011).
Briefly, 8–12 week old wild-type Sprague Dawley rats were euthanized
and the globes were excised. The retina was dissected free from retinal
pigmented epithelium and cut radially into quarters. Neural retina was
then flat-mounted with the photoreceptor side down on polytetra-
fluoroethylene membranes (EMD Millipore) at an air-fluid interface
overlying culture media composed of Neurobasal-A media with 2%
B27 supplement, 1% N2 supplement, L-glutamine (0.8 mM), penicillin,
and streptomycin in humidified conditions at 35C and 5% CO2. Half
of the culture media was exchanged on Day 1 of culture, and then
every second day thereafter.
For co-culture experiments, dissociated cells were washed with PBS
before being suspended at a concentration of 500–2500 cells/ml in
retinal explant culture media. Using a standard 10 ml pipette, a 2 ml
droplet of cell suspension was placed on the RGC surface of each
retinal explant.
In some experiments, retinal explants were treated with cell culture
conditioned media, addition of purified proteins (Table 2), and/or
inhibitors of molecular signalling pathways. In all cases, these factors
were diluted in the retinal explant culture media at the concentrations
indicated. To ensure adequate exposure to the RGC layer, 2–5 ml of
complete culture media containing experimental factors were pipetted
directly onto the RGC surface of explants daily. Anti-PDGF antibody
(EMD Millipore catalogue no. 06-127, goat polyclonal antibody recog-
nizing PDGF-AA, -AB, and -BB) and normal goat IgG (Santa Cruz
Biotechnologies) were each added to the culture media at 35 mg/ml.
Small molecular inhibitors of PDGF receptor kinase (AG1296, EMD
Millipore) or phosphatidylinositol 3 (PI3) kinase (LY294002, Cell
Signaling Technologies) were added to culture media at 45 mM and
75 mM, respectively.
Conditioned media
To obtain cell-conditioned media, cell cultures were grown to 90%
confluence in plastic culture flasks. Then, the growth media was
removed, cells were rinsed three times with PBS, and serum-free
DMEM was added. Cells were cultured for 72–96 h in this medium
and then the conditioned media were collected. Conditioned media
were concentrated using Amicon Ultra-15 centrifugal filter units
(3 kDa normal molecular weight limit, EMD Millipore). Pre-concen-
trated and post-concentrated volumes were used to determine fold
changes in protein concentration. To measure the concentration of
specific cytokines, chemokines and other proteins (Table 1), condi-
tioned media was analysed using commercially available multiplexed
antibody-based assays (xMAP, Luminex). All assays were conducted
according to the manufacturer’s recommendations. Twenty-five micro-
litres of concentrated conditioned media was analysed per sample in
triplicate, using unconditioned, concentrated DMEM as a negative
control. A minimum of three independent samples of concentrated
conditioned media were analysed per cell type. Reported concentra-
tion measurements are corrected for fold-concentration of conditioned
media that was analysed, and correlate to levels found in un-concen-
trated conditioned media. All xMAP assays were analysed using a
Luminex 200 platform and data were collected using Bio-Plex
ManagerTM software. To analyse the secreted concentration of throm-
bospondin 1, an ELISA kit (R&D Systems) was used according to the
manufacturer’s protocol using three independent samples of concen-
trated media per cell type, each run in triplicate.
Human MSC conditioned media was fractionated based on molecu-
lar weight by fast protein liquid chromatography using a Sephacryl
gel filtration column (HiPrepTM Sephacryl S-200HR, GE Healthcare).
A starting volume of 2 ml of concentrated human MSC conditioned
media was applied to the column and run according to manufacturer
recommendations at 0.5 ml/h in 50 mM NaPO4, 0.15 M NaCl running
buffer. Eight samples of 40 ml each were collected during the fraction-
ation and each was concentrated between 50- and 60-fold using
Amicon Ultra-15 centrifugal filter units (3 kDa normal molecular
weight limit). Bicinchoninic acid (BCA) assays of the concentrated frac-
tions showed that fractions 1–3 contained the majority of protein
(0.266 mg/ml in fraction 1, 0.284 mg/ml in fraction 2, and
0.025 mg/ml in fraction 3), whereas little to no protein was detected
in fractions 5–8. SDS-PAGE of fractions 1–3 shows separation of pro-
teins by molecular weight (Fig. 3C). Because of their detectable protein
levels, fractions 1–3 were further used to treat retinal explants. Retinal
explants were treated with concentrated fraction 1, fraction 2, fraction
3 or concentrated column running buffer by applying a 2.5 ml bolus to
the surface of the explants and 4 ml of fractionated media or running
buffer to the base media once daily.
Animal glaucoma model
Ocular hypertension was induced using a modification of the method
developed by Levkovitch-Verbin et al. (2002). Briefly, rats were anaes-
thetized with ketamine (50 mg/kg) and xylazine (10 mg/kg) injected
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intraperitoneally and were placed in front of a slit-lamp equipped with
a 532 nm diode laser, which delivered 0.7 W pulses for 0.6 s. Fifty to
60 laser pulses (50 mM diameter) were directed to the trabecular mesh-
work 360 around the circumference of the aqueous outflow area of
the left eye. Animals were treated twice, 1 week apart. Contralateral
fellow eyes served as untreated controls. Immediately before each of
the two laser treatments, PDGF or vehicle control was locally admin-
istered through 3 ml intravitreal injection through the superior nasal
retina using a 30 G needle on a 5 ml glass Hamilton syringe.
Solutions for injection were masked, and the researchers were blinded
to the treatment or control status of each animal until final analysis of
the entire experiment had been completed. Care was taken to ensure
that the lens was not damaged and that the retinal blood supply was
not affected. Three different treatment groups were analysed: PBS
only (n = 15); PDGF-AA in PBS (1.5 mg delivered at 0.5 mg/ml;
n = 15); and PDGF-AB in PBS (1.5 mg delivered at 0.5 mg/ml; n = 15).
Intraocular pressure was measured bilaterally under anaesthesia before
and 24 h after each laser treatment, and then weekly thereafter using
the TonoLab rebound tonometer (Tiolat Oy). Tonometry was per-
formed within 5 min of anaesthesia onset and always between the
hours of 9:00 am and 11:00 am. Cumulative intraocular pressure ex-
posure for each eye was calculated as the integral of the intraocular
pressure over the 4-week period beginning with the first laser
treatment.
Histology and histological analyses
Retinal tissue was processed to quantify survival of RGC layer cell
populations, as described previously (Bull et al., 2011). Retinal explant
tissue was fixed by overnight immersion in 4% paraformaldehyde at
4C, followed by cryoprotection in 30% sucrose for 24 h at 4C. Tissue
was frozen and cryosectioned at 14 mm. Transverse sections were sim-
ultaneously blocked and permeabilized by incubation in 0.1% TritonTM
and 5% normal goat serum in PBS (blocking solution) for 1 h at room
temperature. Sections were incubated in primary antibody diluted in
blocking solution overnight at 4C, before incubation with secondary
antibody diluted in blocking solution for 3 h at room temperature.
Nuclei were counterstained with DAPI. Primary antibodies used
were: mouse anti-Islet-1 (clone 39.4D5, 1:500, hybridoma developed
by T. Jessell and S. Brenner-Morton, concentrate from the
Developmental Studies Hybridoma Bank, University of Iowa), mouse
anti-NeuN (1:100, EMB Millipore), mouse anti-b-III-tubulin (1:2000,
Promega), mouse anti-human nuclear antigen (1:500, EMB
Millipore), rabbit anti-glial fibrillary acid protein (GFAP, 1:500,
Table 1 Analysis of human MSC and fibroblast secretomes
Secreted factor name Concentration in human
MSC conditioned
media (pg/ml)
Concentration in human
fibroblast conditioned
media (pg/ml)
Secretion ratio human
MSC : human
fibroblast
Adiponectin 0.27  0.39 0.02  0.04 14.3
Basic fibroblast growth factor (FGF-2) 0.20  0.04 0.23  0.39 0.89
Brain derived neurotrophic factor (BDNF) 13.22  2.63 0.02  0.03 589***
Chemokine ligand 14 (CCL-14) 0.10  0.04 0.09  0.04 1.03
Ciliary neurotrophic factor (CNTF) nd 0.02  0.04 Human fibroblast only
Epidermal growth factor (EGF) 0.12  0.13 0.75  0.74 0.16
Epithelial neutrophil activating protein (ENA-78/CXCL-5) 0.44  0.15 0.47  0.18 0.92
Granulocyte colony stimulation factor (G-CSF) nd 0.03  0.06 hFibroblast only
Hepatocyte growth factor (HGF) 120.95  59.70 178.84  88.33 0.68
Insulin-like growth factor 1 (IGF-1) nd nd N/A
Interferon gamma (IFN-g) 0.10  0.02 nd Human MSC only
Interleukin 10 (IL-10) 0.17  0.14 0.01  0.02 14.3
Interleukin 11 (IL-11) 2.22  1.21 nd Human MSC only
Interleukin 13 (IL-13) 0.007  0.009 0.000  0.000 47.5
Interleukin 17 (IL-17) nd nd N/A
Interleukin 1a (IL-1a) 0.040  0.034 0.006  0.009 7.0
Interleukin 2 (IL-2) 0.011  0.009 0.000  0.001 25.5
Interleukin 4 (IL-4) 0.15  0.10 0.02  0.05 6.2
Interleukin 6 (IL-6) 116.23  54.02 0.14  0.20 811**
Leukaemia inhibitory factor (LIF) 1.80  0.90 nd Human MSC only
Melatonin 37.91  5.94 17.48  10.49 2.2*
Nerve grown factor (NGF) 5.96  2.39 0.34  0.12 17.5**
Platelet derived growth factor AA (PDGF-AA) 19.60  12.30 0.04  0.03 523*
Platelet derived growth factor AB/BB (PDGF-AB/BB) 0.44  0.29 0.003  0.005 126*
Stem cell factor (SCF) 0.87  0.21 2.41  1.10 0.36*
Thrombospondin 1 (TSP-1) 143.6  76.7 ng/ml 2.7  0.5 ng/ml 52.3*
Transforming growth factor beta (TGF-b) 2.67  1.91 0.64  0.76 4.17
Tumour necrosis factor alpha (TNF-) 0.015  0.005 0.010  0.004 1.4
Vascular endothelial growth factor (VEGF) 24.77  7.04 13.87  3.79 1.79
Reported concentrations were corrected for centrifuge filtration and represent levels in non-concentrated conditioned media. Concentrations represent the mean of
measurements from at least three independent samples obtained from at least three independent experiments. Data are presented as mean  SD. Mean concentrations
were compared between cell types using two-tailed unpaired Student’s t-tests: *P50.05; **P5 0.01; ***P5 0.001; nd = not detected.
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Dako), and rabbit anti-phospho (Y754)-PDGF receptor alpha (1:50,
Abcam). Alexa Fluor-conjugated secondary antibodies were obtained
from Life Technologies. Terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL) was carried out, with appropriate modifi-
cation, according to the manufacturer’s instructions (GenScript Inc.).
Tissue was processed on microscope slides. Samples were washed
twice in PBS and then permeabilized with 0.1% TritonTM X-100 plus
0.1% sodium citrate (Sigma) in water for 5 min at room temperature.
Samples were incubated in TUNEL reaction mixture, consisting
of equilibration buffer, biotin-11-dUTP, and terminal deoxynucleotidyl
transferase for 60 min at 37C. dUTP binding was detected by
incubation with Alexa Fluor 594-conjugated streptavidin (Life
Technologies) for 1 h at room temperature.
Islet-1 + , NeuN + , b-III-tubulin + and DAPI + cell densities in the RGC
layer were quantified by a masked investigator in at least five sections
per explant, spaced equally across the entirety of the tissue, as
assessed by epifluorescence in fields imaged with a 20 objective.
TUNEL + cells in the RGCL were quantified by a masked investigator
in 1/10 of the sections obtained for each explant (typically at least
12 sections), spaced equally across the entirety of the tissue, and
the total number of TUNEL+ cells per explant was extrapolated by
multiplying the total number counted by 10. Experimental groups
contained at least four retinal explants. Data are presented as
mean  standard error of the mean unless otherwise indicated.
Comparisons between two groups were made using two-tailed
unpaired Student’s t-tests. Comparisons between three or more
groups were made with one-way ANOVA and (if P5 0.05) post
hoc two-tailed Dunnett t-tests compared experimental groups to the
control group.
To assess optic nerves of animals with laser-induced glaucoma
4 weeks after the onset of ocular hypertension, animals were perfused
transcardially with 4% paraformaldehyde under terminal anaesthesia.
Optic nerves were immersed in 4% paraformaldehyde/5% glutaralde-
hyde in phosphate buffer for 7 days at 4C, post-fixed in 1% osmium
tetroxide for 3 h, dehydrated and embedded in Araldite resin for
semi-thin sectioning. Semi-thin (1 mm) transverse sections were cut
from the nerve 2–3 mm distal to the globe, dried onto slides and
stained with 1% toluidine blue. Loss of RGC axons in the optic
nerves of glaucomatous eyes was quantified using an established
semi-quantitative optic nerve grading scheme, as we have described
in detail previously (Marina et al., 2010). Briefly, zones of apparently
homogenous damage were identified under light microscopy (100
magnification) and the percentage contribution of each zone to total
optic nerve cross-sectional area was determined. All optic nerves were
masked throughout the entire analysis process so that observers
performing quantification were unaware of the treatment or control
status of the animal. A representative photograph within each zone
was captured at 630 magnification (representing 0.004 mm2 total
optic nerve area) and the number of axons within each sample
image was quantified using an automated image analysis program
(ImageJ, developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD http://rsb.info.nih.gov/ij/index.html). The
number of axons within each damage zone was compared to the
count obtained from a sample image of the uninjured companion
eye to estimate the percentage of axonal survival. A weighted average
calculation was then used to estimate the percentage of surviving
axons in the total optic nerve for each animal based on the proportion
of the total optic nerve cross-sectional area that each damage
zone represented. Comparisons between the three groups
were made with one-way ANOVA and (if P5 0.05) post hoc two-
tailed Dunnett t-tests compared each PDGF group to the PBS control
group.
Results
Isolation and identification of rat
mesenchymal stem cells
Rat MSCs were isolated and purified from bone marrow aspirates
obtained from the femurs of adult transgenic Sprague Dawley rats
engineered to express GFP under control of the chicken b-actin
promoter. Flow cytometric analysis demonstrated GFP expression
in 96.2% of rat MSCs, as well as expression of CD29, CD44, and
CD90 but not CD34, CD45, CD11b, CD68, or CD11b
(Supplementary Fig. 1). In addition, rat and human MSCs under-
went appropriate differentiation into adipocytes and osteoblasts
after culture in induction media (data not shown).
Retinal ganglion cell neuroprotection
by co-culture with rat mesenchymal
stem cells
Previously, we showed that co-culture of retinal explants with rat
MSCs could prolong RGC survival (Bull et al., 2011). The current
work expanded on those experiments to characterize further the
ability of rat MSCs to protect RGCs from cell death. Rat MSCs
were co-cultured on the inner retinal (vitreous) surface of organo-
typic retinal explants for 7 days. GFP expression allowed tracking
of the rat MSCs within the co-cultures and revealed that rat MSCs
did not migrate into the host neural retinal tissue, but instead
remained as a multi-laminar structure outside of the retinal inner
limiting membrane (Fig. 1), which is consistent with observations
that were previously reported (Johnson and Martin, 2008; Bull
et al., 2011). Quantification of cell survival within the RGC layer
of retinal explants demonstrated that rat MSC co-culture was
associated with a significant attenuation of RGC death at
7 days, compared to without cell co-culture. The number of
total surviving cells (labelled with DAPI) increased from 103  4
to 213  8 cells/mm (P5 0.001, Fig. 1I). To avoid quantification
of astrocytes, microglia, and endothelial cells, which might be
expected to survive more readily in explant culture given that
they did not undergo direct cellular injury (axotomy) during the
explantation process, neurons were immunofluorescently labelled
with antibodies directed against Islet-1 and NeuN. Quantification
confirmed a significant increase in the survival of both Islet-1 +
(13.9  0.9 versus 41.5  1.6 cells/mm, P50.001, Fig. 1A, B
and I) and NeuN + (58.1  2.0 versus 127.3  8.3 cells/mm,
P50.001, Fig. 1C, D and I) neurons in the RGC layer.
Quantification of b-III-tubulin + neurons in the RGC layer also
demonstrated a comparable level of neuroprotection (17.6  1.1
versus 29.7  3.7 cells/mm, P50.05, Fig. 1E–I). Although b-III-
tubulin is a more specific marker for RGCs than either NeuN or
Islet-1, immunoreactivity of neurite processes in addition to cell
bodies made the precise quantification of these cells more difficult
and potentially less accurate in transverse histological sections;
for this reason, further experiments focused on quantification of
nuclear/perinuclear antigens. In accordance with increased cell
survival, rat MSC co-culture also reduced apoptosis in the RGC
layer, as assessed by TUNEL, from 453  70 to 127  2 cells/
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explant (P50.001, Fig. 1J and K). Most TUNEL + nuclei were also
pyknotic or karyorrhexic (Fig. 1J). In addition to increased cell
soma survival, rat MSC co-culture was associated with enhanced
preservation of RGC axons and dendrites. Qualitatively, retinal
explants possessed a thicker nerve fibre layer and more discernible
dendrites in the inner plexiform layer (Fig. 1E–H). Quantitatively,
the inner plexiform layer thickness of rat MSC-treated explants
increased from 45.2  2.6 to 76.1  1.2mm (P50.001, Fig. 1L).
Of note, other layers of the neural retina including the inner nu-
clear layer and outer nuclear layer appeared to be thicker in the
context of rat MSC co-culture.
Retinal ganglion cell neuroprotection by
co-culture with other cell types
Rat retinal explants were co-cultured with human MSC grafts to
determine whether they could also alleviate RGC death. Similar to
observations with rat MSCs, human MSCs remained as a bolus on
the surface of the host neural retina and did not migrate into the
explant (Fig. 2A and B). Quantification of cell density in the RGC
layer demonstrated that human MSC co-culture was associated
with increased survival of Islet-1 + (17.4  1.5 versus 36.6  2.1
cells/mm, P50.001) and NeuN + (47.1  2.3 versus 89.7  4.4
cells/mm, P50.001) neurons compared to without cell co-culture
(Fig. 2C). The specificity of this neuroprotective capacity was eval-
uated by co-culturing retinal explants with human fibroblasts or a
cell line derived from mouse embryonic fibroblasts (NIH-3T3 cells).
Co-culture with either of these two cell types resulted in only a
modest increase in Islet-1 + neuronal survival (21.3  0.8 versus
24.3  0.9 cells/mm for human fibroblasts, P50.01) and no
other signs of neuroprotection compared to without cell co-culture
(Fig. 2D and E). With only weak to no neuroprotective effects
observed with fibroblast co-culture, it was concluded that the
robust neuroprotective properties exhibited by MSCs from multiple
species are not shared by all cell types.
Retinal ganglion cell neuroprotection by
mesenchymal stem cell-conditioned
media
Based on observations that MSCs secrete relatively high levels of
signalling factors that could play a role in neuroprotection, the
effects of media conditioned by 3 days of rat or human MSC culture
were evaluated. Initial experiments demonstrated no detectable
effects on RGC survival when rat MSC conditioned media was
added to retinal explant culture media without further refinement
Figure 2 Retinal ganglion cell neuroprotection by human mesenchymal stem cells. Human mesenchymal stem cells (hMSCs), human
fibroblasts (hfibroblast), or mouse embryonic fibroblasts (NIH-3T3) were co-cultured on the retinal ganglion cell (RGC) surface of retinal
explants for 7 days. Human MSCs were visualized by anti-human nuclear antigen immunofluorescence (A and B, red). Glial cells were
visualized with glial fibrillary acid protein (GFAP) immunofluorescence (A and B, green). Mu¨ller glial endplate processes at the inner
limiting membrane delineated the boundary of the neural retina. Red fluorescence at the outer retina (B) represents autofluorescence.
All nuclei were stained with DAPI. Scale bars: A and B = 100mm. Quantification of neuronal survival in the RGC layer (C–E). **P50.01;
***P50.001; NS = not significant. Error bars represent standard error of the mean. Control indicates without cell co-culture.
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(data not shown). We hypothesized that secreted factors may have
been diluted to subtherapeutic concentrations in conditioned media
whereas paracrine signals from MSCs situated in near proximity to
RGCs reach higher concentrations in experiments with cell co-cul-
ture. Therefore, filter centrifugation was used to concentrate rat
MSC conditioned media by 25–35-fold. Addition of concentrated
rat MSC conditioned media to the explant culture media (1:133)
and daily placement of a 2.5 ml bolus of concentrated rat MSC con-
ditioned media directly onto the inner retinal surface of the explants
resulted in significant neuroprotection of Islet-1 + (13.7  0.6 versus
21.9  0.3 cells/mm, P50.001) and NeuN + (66.9  3.0 versus
79.6  1.9 cells/mm, P50.01) neurons compared to similar treat-
ment with concentrated, unconditioned DMEM (Fig. 3A). Thus, the
neuroprotective effect of MSC-derived factors appeared to be con-
centration-dependent.
The neuroprotective potentials of concentrated (25–55-fold)
human MSC and human fibroblast conditioned media obtained
were also investigated. Whereas human fibroblast conditioned
media had no effect on RGC survival in retinal explants, factors
secreted from human MSCs demonstrated a modest but statistically
significant increase in Islet-1 + neuron density in the RGC layer
(24.5  1.6 versus 30.6  1.4 cells/mm, P50.05, Fig. 3B) com-
pared to treatment with concentrated, unconditioned DMEM.
To determine whether a particular fraction of the MSC secretome
could be identified as accounting for the RGC neuroprotection
observed, human MSC conditioned media was fractionated using
fast protein liquid chromatography. Three fractions each contained
protein (Fig. 3C) and were used to treat retinal explants. Only frac-
tion 1 demonstrated neuroprotective activity, with an increase in
Islet-1 + neurons from 24.6  1.3 to 36.4  2.6 cells/mm
(P5 0.05) and an increase in NeuN + neurons that did not reach
statistical significance (56.1  8.8 versus 65.5  2.6 cells/mm,
P = 0.3, Fig. 3D) compared to treatment with concentrated, uncon-
ditioned DMEM. It was notable that RGC cell survival was generally
greater when rat MSCs or human MSCs were co-cultured directly on
the explant surface as compared to treatment with rat MSC or
human MSC conditioned media, or fractions thereof.
Analysis of the human mesenchymal
stem cell secretome and identification
of neuroprotective components
A clear effect on RGC survival of factors secreted by MSCs
into conditioned media prompted a careful analysis of the
human MSC secretome, focusing specifically on proteins with
Figure 3 Retinal ganglion cell neuroprotection by mesenchymal stem cell conditioned media. DMEM was conditioned by 72–96 h
incubation with rat or human mesenchymal stem cells (hMSCs) or human fibroblasts. Control DMEM was unconditioned. Conditioned
media was then concentrated 25 to 55-fold by centrifuge filtration. Concentrated rat MSC (A) or human MSC (B) conditioned media was
added to retinal explant media and to the retinal ganglion cell (RGC) surface of retinal explants daily for 7 days. Neuronal survival in the
RGC layer was quantified. Human MSC conditioned media was fractionated by fast protein liquid chromatography (C). Retinal explants
were treated with individual human MSC conditioned media fractions (F1, F2, F3) or with human MSC co-culture as a positive control, and
RGC survival was quantified (D). *P50.05; **P50.01; ***P50.001. Error bars represent standard error of the mean.
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known or purported effects on neuronal survival. Also analysed
were factors involved in regulating inflammation, as MSCs possess
well-documented immunomodulatory properties that have been
proposed to play a role in neuroprotection in other models.
Since human fibroblast conditioned media demonstrated no
effect on RGC survival, it was used as a negative control.
Conditioned media from these two cell cultures were analysed
using multiplexed xMAP factor arrays and ELISAs. The results
are presented in Table 1. Eleven proteins were identified that
were secreted at significantly higher levels by human MSCs as
compared to human fibroblasts including brain-derived neuro-
trophic factor (BDNF), interferon gamma, interleukin (IL)-11, IL-
6, leukaemia inhibitory factor (LIF), melatonin, nerve growth
factor (NGF), platelet-derived growth factor (PDGF)-AA, PDGF-
AB/BB, stem cell factor, and thrombospondin 1.
Further experiments explored the effect on RGC survival of a
subset of these proteins (BNDF, IL-6, LIF, melatonin, NGF, PDGF-
AA, PDGF-AB, and thrombospondin 1) as well as pigment epithe-
lium-derived factor (PEDF), IL-2, IL-13, secreted protein acidic and
rich in cysteine (SPARC, also known as osteonectin), and galectin-
1, which are secreted by MSCs and may play a role in neuronal
survival or regeneration (Sholl-Franco et al., 2001; Bampton et al.,
2005; Okada et al., 2005; Yabe et al., 2010). First, retinal explants
were cultured in standard media with the addition of purified pro-
teins as a cocktail at previously reported bioactive concentrations
(Table 2). Treatment with this secreted factor cocktail significantly
increased survival of Islet-1 + (28.7  2.1 versus 37.2  1.8 cells/
mm, P50.05, Fig. 4A) and NeuN + (79.5  6.6 versus
103.5  4.5 cells/mm, P50.05, Fig. 4B) neurons compared to
vehicle treatment. The cocktail was then split into subgroups
based on signalling mechanism/molecular family, along with two
residual ‘miscellaneous’ subgroups composed of molecules that did
not fit clearly into the other subgroups (Table 3). Treatment of
retinal explants with subgroups of purified protein revealed that
several groups conferred protection to RGCs (Fig. 4C and D). The
only subgroup that was not associated with increased RGC sur-
vival was that composed of IL-6, IL-11, and LIF. In contrast, the
subgroup consisting of PDGF-AA, PDGF-AB, PEDF, and IL-2 was
associated with the greatest level of RGC survival compared to
vehicle treatment (Islet-1: 23.1  0.6 versus 37.3  2.0 cells/
mm, P50.001; NeuN: 34.9  3.5 versus 59.3  2.3 cells/mm,
P50.001), similar to that achieved with human MSC co-culture
(Fig. 4C and D). Finally, retinal explants were treated with each
factor in the PDGF subgroup individually. This revealed that
PDGF-AA and PDGF-AB alone protected RGCs to roughly the
same extent as the complete subgroup of four factors, whereas
IL-2 and PEDF alone were not associated with significant changes
in RGC survival (Fig. 4E and F). Treatment of retinal explants with
a combination of PDGF-AA and PDGF-AB revealed dose-depend-
ent RGC neuroprotection (Fig. 4G).
Given that PDGF seemed to confer neuroprotection to RGCs in
retinal explant culture and was highly secreted by human MSCs,
immunohistochemistry was used to identify PDGF receptor activa-
tion in RGCs under various conditions. In untreated explants, few
RGCs were immunopositive for phosphorylated (activated) PDGF
receptor (Fig. 5A). After co-culture with human MSCs (Fig. 5B and
E) or treatment with purified PDGF protein (Fig. 5C), marked
PDGF receptor activation was observed in retinal neurons co-
labelled with antibodies against NeuN. Activation of the PDGF
receptor could also be found co-localized with RGCs expressing
b-III-tubulin (Fig. 5F). In addition, PDGF receptor activation was
observed outside of the RGC layer, likely in retinal astrocytes or
Mu¨ller cell processes (Fig. 5F). Interestingly, strong PDGF receptor
activation also took place within the human MSC graft, suggesting
that PDGF signalling may play a role in human MSCs in co-cul-
ture. Addition of a soluble anti-PDGF antibody blocked the PDGF
receptor activation that occurred in RGCs in response to treatment
with purified PDGF protein (Fig. 5D). The relationship between
PDGF receptor activation and RGC survival was assessed by block-
ing PDGF signalling. Incubation with anti-PDGF neutralizing anti-
body accelerated RGC death in untreated retinal explant cultures,
and also completely blocked the neuroprotective effects of both
human MSC co-culture and treatment with purified PDGF protein
(Fig. 5G–I). In contrast, non-specific species-matched IgG had no
Table 2 Composition of secreted factor cocktail
Factor name Final concentration (ng/ml) Vendor source
Brain-derived neurotrophic factor (BDNF) 50 Sigma #B3795
Galectin 1 10 PeproTech #450-39
Interleukin 13 (IL-13) 50 PeproTech #200-13
Interleukin 2 (IL-2) 25 PeproTech #200-02
Interleukin 6 (IL-6) 50 PeproTech #200-06
Leukaemia inhibitor factor (LIF) 50 Sigma #L5283
Melatonin 100 Sigma #M5250
Nerve growth factor (NGF) 50 PeproTech #450-01
Pigment epithelium derived factor (PEDF) 50 PeproTech #130-13
Platelet derived growth factor (PDGF)-AA 50 PeproTech #100-13A
Platelet derived growth factor (PDGF)-AB 50 PeproTech #100-00AB
Secreted protein acidic and rich in cysteine (SPARC) 25 PeproTech #120-36
Thrombospondin 1 (TSP-1) 100 Sigma #SRP4805
Representative data from experiments comparing treatment of retinal explants with secreted factor cocktail versus vehicle are presented in Fig 4A
and B. Indicated factors were obtained in purified protein form and added at the indicated concentrations to retinal explant culture media.
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Figure 4 Retinal ganglion cell neuroprotection by factors enriched in the MSC secretome. Retinal explants were cultured using standard
protocols with or without the addition of various purified proteins or vehicle (control) to the culture media. A cocktail of 13 factors detailed
in Table 2 was added to the culture media (A, B). Factors were sub-divided as indicated in Table 3 and added to the culture media (C, D).
Factors in the PDGF group were further sub-divided and added to the culture media at the same final concentrations as indicated in Table
3 (E, F). The dose-dependence of PDGF neuroprotection was evaluated by adding each of these factors at the indicated concentration to
the culture media (G). Treatment with rat MSC (rMSC) or human MSC (hMSC) co-culture was used as a positive control for comparison.
Neuronal survival in the RGC layer was quantified. *P50.05; **P50.01; ***P50.001. Error bars represent standard error of the mean.
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effect on human MSC-mediated neuroprotection (Fig. 5G).
Furthermore, suppression of PDGF signalling using a small
molecule inhibitor of PDGF receptor kinase, AG-1296, had little
effect on RGC survival in untreated explant cultures but attenu-
ated the neuroprotective effects of both human MSC co-culture
and treatment with purified PDGF protein (Fig. 5J and K). Similar
results were obtained using a small molecule inhibitor of PI3 kinase
(Fig. 5L and M), which lies downstream in the PDGF receptor
signalling cascade (Fantl et al., 1992).
Platelet-derived growth factor-mediated
retinal ganglion cell neuroprotection in
an in vivo glaucoma model
Having demonstrated that PDGF-AA and PDGF-AB confer robust
neuroprotection to RGCs in a retinal explant culture model, it was
hypothesized that these proteins would be similarly protective to
the optic nerve in an in vivo model of RGC neurodegeneration. To
test this, ocular hypertension was induced in one eye of adult rats
by laser photocoagulation of the trabecular meshwork while the
fellow eye served as a control. Laser treatments were administered
twice, spaced 1 week apart, and in both cases immediately pre-
ceded by intravitreal injections of PDGF-AA (1.5mg, n = 15),
PDGF-AB (1.5mg, n = 15), or PBS as a vehicle control (3 ml,
n = 15). Animals were sacrificed 4 weeks following the initial in-
duction of ocular hypertension and optic nerves were processed to
quantify RGC axonal survival. Tonometry demonstrated a strong,
consistent, and transient rise in intraocular pressure induced by
laser treatment compared with fellow untreated eyes (Fig. 6A-
C). Peak intraocular pressure, mean intraocular pressure, and cu-
mulative integral intraocular pressure exposure (expressed as
mmHg  days) were significantly greater in treated eyes compared
with fellow controls in all three treatment groups (P50.001 for all
comparisons, Fig. 6D–F). The peak intraocular pressures (Fig. 6D),
mean intraocular pressures (Fig. 6E) and cumulative integral
intraocular pressure exposures (Fig. 6F) of each of the two
PDGF groups were statistically similar to those of the PBS control
group for ocular hypertension eyes (P40.05). PBS treatment was
associated with a survival of 68.2  4.4% of RGC axons at
4 weeks after the initial laser treatments, whereas treatment
with PDGF-AA was associated with increased RGC axonal survival
to 93.6  2.9% (P5 0.001) and PDGF-AB with increased RGC
axonal survival to 96.7  2.0% (P50.001, Fig. 6G). To account
for variability in intraocular pressure elevation between animals
and the fact that the PDGF-AB group experienced overall greater
intraocular pressure exposure than the PBS control group, RGC
axonal loss was normalized to cumulative excess intraocular pres-
sure exposure (RGC axonal loss divided by integral intraocular
pressure exposure in the ocular hypertension eye minus integral
intraocular pressure exposure in the control eye). RGC axons were
lost at a rate of 2.9  103 per cent/mmHg  day with PBS treat-
ment, whereas the rate of RGC axonal loss was reduced to
9.3  104 per cent/mmHg  day by PDGF-AA treatment
(P5 0.05) and to 2.9  104 per cent/mmHg  day by PDGF-
AB treatment (P5 0.001, Fig. 6H). Representative photomicro-
graphs from optic nerves of animals treated with PBS (Fig. 6I),
PDGF-AA (Fig. 6J), and PDGF-AB (Fig. 6K) are shown.
Discussion
The present study demonstrates that MSCs derived from both
human and rat bone marrow possess a potent neuroprotective
capacity capable of enhancing RGC survival in retinal explant cul-
ture. Moreover, our comparison of more than 29 factors in the
secretomes of human MSCs and human fibroblasts identified
PDGF as a particularly potent neuroprotectant molecule that was
highly secreted by MSCs. In fact, the neuroprotective effect
observed in the present study by intravitreal administration of
Table 3 Composition of secreted factor subgroups
Group name Factors in group Final concentration (ng/ml) Vendor source
IL-6 Interleukin 6 (IL-6) 50 PeproTech #200-06
Interleukin 11 (IL-11) 50 PeproTech #200-11
Leukaemia inhibitory factor (LIF) 50 Sigma #L5283
Misc 1 Melatonin 100 Sigma #M5250
Thrombospondin 1 (TSP-1) 100 Sigma #SRP4805
Secreted protein acidic and rich in cysteine (SPARC) 25 PeproTech #120-36
Galectin-1 10 PeproTech #450-39
Misc 2 Interleukin 13 (IL-13) 50 PeproTech #200-13
Interferon gamma 50 PeproTech #300-02
PDGF Platelet derived growth factor (PDGF)-AA 50 PeproTech #100-13A
Platelet derived growth factor (PDGF)-AB 50 PeproTech #100-00AB
Pigment epithelium derived factor (PEDF) 50 PeproTech #130-13
Interleukin 2 (IL-2) 25 PeproTech #200-02
NTF Brain derived neurotrophic factor (BDNF) 50 Sigma #B3795
Nerve growth factor (NGF) 50 PeproTech #450-01
Representative data from experiments comparing treatment of retinal explants with secreted factor subgroups versus vehicle are presented in Fig. 4C and D. Indicated
factors were obtained in purified protein form and added at the indicated concentrations to retinal explant culture media. Proteins in the IL-6 group signal through the
gp130 receptor complex. Proteins in the PDGF group signal through, among many pathways, PI3 kinase. Proteins in the neurotrophic factor (NTF) group signal through Trk
receptors.
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Figure 5 Role of PDGF signalling in retinal ganglion cell neuroprotection by MSCs. Retinal explants were cultured alone (A); with human
MSCs (B, E and F); with PDGF-AA + PDGF-AB (50 ng/ml) added to the culture media (C); or with PDGF-AA + PDGF-AB (50 ng/ml) plus
anti-PDGF IgG (35mg/ml) added to the culture media (D). Retinal ganglion cell (RGC) layer neurons were visualized with NeuN (A–E) or b-
III-tubulin (F) immunofluorescence (red) and PDGF signalling was detected with phospho-PDGF receptor immunofluorescence (green).
Nuclei were visualized with DAPI (blue). Higher magnification image of the RGC layer in B is depicted as individual channels in E’ and E’’
and merged in E. Scale bars: A–E= 200mm; F= 25 mm. Retinal explants were cultured alone, or with the addition of PDGF-AA + PDGF-AB
(50 ng/ml) to the culture media, or with human MSC co-culture for 7 days. Half of the explants from each group were additionally treated
with non-specific anti-goat IgG (35mg/ml, G); anti-PDGF IgG (35 mg/ml, G–I); small molecular inhibitor of PDGF receptor kinase, AG1296
(45 mM, J–K); or small molecule inhibitor of PI3 kinase, LY294002 (75 mM, L–M). *P50.05; **P5 0.01; ***P50.001. Error bars
represent standard error of the mean. Control indicates without cell co-culture or addition of PDGF to growth media.
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Figure 6 Optic nerve protection by PDGF treatment in an in vivo glaucoma model. Unilateral ocular hypertension (OHT) was induced by
laser trabecular meshwork photocoagulation on Days 0 and 7 of the experiment, immediately preceded by intravitreal injection of PBS
(3 ml, n = 15), PDGF-AA (1.5mg, n = 15), or PDGF-AB (1.5 mg, n = 15). Intraocular pressure (IOP) measurements over time are shown in
A (PBS), B (PDGF-AA), and C (PDGF-AB). Peak intraocular pressure (IOP; D), mean intraocular pressure (E), and cumulative integral
intraocular pressure exposure (F) were calculated for ocular hypertension and control eyes in each group. Optic nerve survival was
quantified as per cent surviving RGC axons in the ocular hypertension optic nerve as compared to the contralateral control eye (G). The
rate of RGC axon loss normalized to cumulative excess intraocular pressure exposure is shown in H. Representative photomicrographs of
optic nerve cross sections are shown for treatment with PBS (I), PDGF-AA (J), and PDGF-AB (K). *P50.05, ***P5 0.001, compared to
the PBS control group. Error bars for intraocular pressure data represent standard deviation. Error bars for RGC survival data represent
standard error of the mean. Scale bar = 10 mm.
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PDGF protein in rats with laser-induced ocular hypertension was
extremely robust, and even stronger than that seen following
intravitreal grafting of rat MSCs derived from two different strains
of rat, where RGC axonal survival in the context of a comparable
level of injury increased from 74.7% to 92.1% and from 61.7% to
89.3% (Johnson et al., 2010). Interestingly, the current study also
identified a necessity for PDGF signalling in the mechanism of
action of MSC-mediated neuroprotection, such that blockade of
PDGF signalling or downstream pathways eliminated the beneficial
effect of the MSCs.
The present experiments extend the findings published in
previous studies. Yu et al. (2006) noted a 16% increase in RGC
survival at 12 weeks following induction of intraocular pressure
elevation by episcleral vein ligation when MSCs were injected
into the vitreous at Week 8. Li et al. (2009) reported a 33%
increase in RGC survival at 4 weeks after ischaemia/reperfusion
injury to the retina with concurrent MSC transplantation. We
previously showed that intravitreal transplantation of rat MSCs
at the time of ocular hypertension induction by laser photocoagu-
lation of the trabecular meshwork leads to a 460% reduction in
the loss of RGC axons in the optic nerve (Johnson et al., 2010).
MSCs derived from umbilical cord blood also appear to confer
neuroprotection to RGCs following optic nerve crush injury
(Zhao et al., 2011) and optic tract transection (Zwart et al.,
2009). Moreover, we previously reported on the effects of rat
MSC co-culture with organotypic retinal explants and, in agree-
ment with the current study, observed significant increases in RGC
survival at both 4 and 7 days ex vivo (Bull et al., 2011). Some
studies have attempted to delineate the mechanism by which
MSC-mediated RGC neuroprotection occurs, and in most cases
have focused on the elaboration of various neurotrophic factors.
Factors found to be expressed by MSCs in vivo or upregulated in
the eye after MSC transplantation, at the messenger RNA or
protein levels, include BDNF, NGF, CNTF, GDNF, NT-3, HGF,
b-FGF, and TGF-b (Yu et al., 2006; Li et al., 2009; Zwart et al.,
2009; Zhao et al., 2011). However, in most cases the number of
factors evaluated was relatively narrow, the direct effects of many
of these factors on RGC survival were not evaluated, and the
necessity of these factors in conferring RGC protection by MSCs
was not tested. Each of those limitations was addressed by the
present study.
The MSC secretome is being increasingly recognized as a po-
tential source of factors capable of protecting patient tissues
throughout the body in the context of insult, injury or disease.
The relevance of MSC-derived factors to ischaemic heart disease
was recently reviewed (Ranganath et al., 2012). It has also been
shown that intravenous administration of MSC conditioned media
to rats with experimental kidney disease improves renal function
(van Koppen et al., 2012). Although MSCs secrete an extremely
large number of factors at varying concentrations that likely exert
wide-ranging bioactive effects, attempts at characterizing the MSC
secretome have led to the identification of specific molecules that
might be relevant to treating various pathological processes. Liquid
chromatography tandem mass spectrometry identified the protein
Cyr61 as being highly secreted by MSCs, and elaboration of this
factor accounted for the angiogenic effects of MSC conditioned
media in vivo, which could prove useful in promoting wound
healing (Estrada et al., 2009). The same method identified prosa-
posin as being highly secreted by a subset of beta-III-tubulin-
expressing mouse MSCs cultured under specific conditions;
prosaposin was subsequently found to reduce apoptosis in neur-
onal cultures stressed with 6-hydroxydopamine (Li et al., 2010).
Antibody array screening of MSC conditioned media, combined
with fractionation based on heparin binding affinity, was used to
generate an MSC-derived chemokine cocktail effective in dampen-
ing the inflammatory process in hepatic failure (Parekkadan et al.,
2007). Thus, continued research aimed at fully characterizing the
MSC secretome and evaluating the bioactive effects of its con-
stituents could prove useful to the clinical translation of therapies
for many different sorts of pathology, either by identifying the
mechanisms by which MSC transplantation confers benefit or by
identifying molecules that could be delivered independently of
MSC transplantation to treat disease.
The PDGF family contains four members, PDGF-A, -B, -C, and
-D that homodimerize, or in the case of PDGF-AB, heterodimerize.
Secreted PDGF dimers signal through receptor tyrosine kinases
consisting of homo- or heterodimers of PDGF receptor  and b.
PDGFs are known to play a significant role in development and
also in the maintenance and pathology of various mesenchymal
tissues (Andrae et al., 2008). In addition, PDGFs appear to play a
role in the susceptibility of CNS neurons to cell death after insult.
For example, knock out of PDGF receptor b in neurons makes
them more susceptible to excitotoxic death (Ishii et al., 2006).
Administration of PDGF-B confers neuroprotection after NMDA
administration whereas knockdown of PDGF-B exacerbates neur-
onal death (Egawa-Tsuzuki et al., 2004). More specifically, PDGFs
may play a role in the survival and degeneration of RGCs. PDGF-
CC has been identified as a potent neuroprotective molecule for
RGCs, which reduces RGC death after axotomy by modulating
GSK3b signalling (Tang et al., 2010). PDGF receptors  and
b are expressed in the RGC layer and their activation leads to
downstream signalling through the PI3 kinase/Akt pathway
(Biswas et al., 2008). PDGF-B is expressed by RGCs and its level
declines after optic nerve transection, which has been hypothe-
sized to play a role in RGC death after injury (Mekada et al.,
1998). Finally, treatment with PDGF-AA has been shown to
attenuate oxidative stress-induced cell death in RGC-5 cells via
PI3 kinase signalling (Kanamoto et al., 2011). The results of the
present study extend these results by demonstrating that PDGF-
AA and PDGF-AB confer neuroprotection to RGCs in the context
of axotomy and ex vivo culture in a PI3 kinase-dependent
manner. Moreover, we have now also demonstrated that intrao-
cular injection of PDGF-AA or PDGF-AB protects the optic nerve
in an in vivo model of experimental glaucoma. Thus, while the
neuroprotective effects of PDGF family members have been
demonstrated in other contexts previously, the present results
certainly suggest that PDGF signalling may represent a target for
RGC neuroprotection in glaucoma that should be explored further.
In addition, to our knowledge, these data are the first to identify
PDGF signalling as a key player in the mechanism of MSC-
mediated neuroprotection.
PDGF is also known to play an important role in MSC prolifer-
ation (Qiu et al., 2013) and differentiation, particularly into
osteoblasts and chondrocytes (Ng et al., 2008). Furthermore,
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PDGF signalling is important for maintaining the commitment of
MSCs to mesenchymal lineage and blockade of PDGF signalling
increases the multipotentiality of these cells (Ball et al., 2012). In
the present study, we observed strong activation of PDGF recep-
tors in MSCs co-cultured with retinal explants, suggestive that
PDGF signalling in MSCs could play an important role in the retinal
neuroprotective effects observed after co-culture. It should be
noted that although loss of RGC neuroprotection was seen
following blockade of PDGF signalling in retinal explant/MSC
co-cultures, it is unclear whether this effect was mediated specif-
ically by reduced PDGF signalling in RGCs, in MSCs, or a combin-
ation of the two. It is possible that blockade of PDGF signalling in
the MSC graft altered its phenotype such that additional neuro-
protective MSC properties (beyond PDGF delivery to RGCs) were
modified. Indeed, identification of high secretion levels of numer-
ous factors by MSCs, which independently conferred RGC protec-
tion, suggests that PDGF delivery by MSCs is likely not the sole
mechanism underlying the observed neuroprotection.
We have also demonstrated that MSCs secrete high levels of
several neurotrophic factors, including BDNF and NGF, which are
known to support RGC survival, and were shown here to protect
RGCs in retinal explant culture. Furthermore, we identified a high
molecular weight fraction of MSC conditioned media that pos-
sessed enhanced neuroprotective activity. One high molecular
weight protein in our secreted factor cocktail, thrombospondin
1, is a trimer of three glycoprotein chains having molecular
weights of 140 kDa each. Thrombospondin 1 was included in
the Misc1 factor subgroup cocktail, which demonstrated RGC
neuroprotective activity in the current study (Fig. 4C and D),
and thrombospondin 1 has been shown previously to be an
MSC-derived factor capable of protecting RGCs in dissociated
cell culture (Yu et al., 2008). It is likely that thrombospondin 1,
and possibly other yet undefined factors from the MSC secretome,
contribute to RGC neuroprotection following transplantation or
co-culture. The nearly complete elimination of MSC-mediated
RGC neuroprotection by PDGF signalling blockade that was
observed in the current study might indicate that PDGF not only
promotes RGC survival by direct action, but also supports MSC
behaviours that confer additional RGC neuroprotection. The role
that PDGF signalling may play in controlling MSC neuroprotective
actions warrants further investigation. Nonetheless, a protective
role for PDGF signalling within RGCs was clearly defined by the
present study.
The current study failed to demonstrate a neuroprotective effect
on RGCs after treatment with soluble IL-2 or PEDF, which is in
contrast to previous studies that noted increases in RGC survival
conferred by these factors. The IL-2 receptor is expressed in the
inner retina at postnatal day (PND)-2 and treatment of retinal
explants derived from PND-2 rats increased RGC survival at 2
and 5 days of culture in a JAK and ERK1/2-dependent manner
(Marra et al., 2011). PEDF increases RGC survival in dissociated
cells cultured under both normoxic and hypoxic conditions
(Unterlauft et al., 2012), as well as following neurotrophic factor
withdrawal and glutamate-induced excitotoxicity (Pang et al.,
2007). Moreover, intraocular viral gene transfer of PEDF improved
RGC survival and electrophysiological function in rats following
ischaemic-reperfusion injury and NMDA-induced excitotoxicity
(Miyazaki et al., 2011). It is unclear why the current experiments
demonstrated a lack of neuroprotection conferred by these two
factors in retinal explants, but differences in experimental systems
including the age of host tissue, type of host tissue (e.g. retinal
explant culture versus dissociated cell culture), type of RGC injury,
and dosing regimens could account for the disparity between
results. A possible neuroprotective role of IL-2 and PEDF should
be investigated further using in vivo models.
The current study extends our previous findings by showing
that human MSCs are capable of protecting RGC cell bodies
and neurite processes following injury. Furthermore, several
secreted factors that could account for this bioactivity, the most
potent of which was PDGF, were identified. These observations,
combined with a growing body of literature that has demonstrated
RGC neuroprotection using in vivo models of RGC/optic nerve
degeneration, support our hypothesis that intravitreal MSC trans-
plantation might be applied to the long-term management of
chronic optic neuropathies such as glaucoma. MSCs inherently
possess neuroprotective properties that could attenuate the loss
of RGCs over time. In addition, studies have demonstrated that
the neuroprotective phenotype of MSCs can be augmented to
greater-than-baseline levels, for instance by in vitro treatment
with defined signalling factor cocktails (Levkovitch-Verbin et al.,
2010) or viral transduction to overexpress growth factors (Harper
et al., 2011). This approach has been shown to improve both
structural and functional outcomes in models of optic nerve
neurodegeneration. The theoretical benefits of local stem cell
transplantation for the treatment of chronic conditions such as
glaucoma include potentially sustained long-term delivery of
neuroprotective substances independent of patient adherence to
therapy. Moreover, MSCs appear to target multiple neuroprotec-
tive pathways through the simultaneous secretion of a multitude
of factors, a characteristic that could be especially beneficial in a
process like glaucoma where many pathogenic pathways appear
to contribute to disease progression. The safety of local MSC
transplantation could potentially be increased by encapsulating
the graft in a device that is permeable to soluble factors, but
which sequesters the transplanted cells beyond the visual axis
and offers the possibility of complete surgical removal should an
adverse event occur. In fact, such a device loaded with cells that
secrete CNTF is the focus of a registered trial for patients with
glaucoma (NCT01408472). Alternatively, continued research
aimed at elucidating the mechanism(s) of MSC-mediated neuro-
protection may lead to the discovery of as yet unappreciated
neuroprotection targets. The identification of an unexpectedly
large effect size for PDGF-mediated neuroprotection in the present
study suggests that it may represent such a target for the treat-
ment of glaucoma. In fact, direct injection of PDGF protein at
regular intervals could represent a viable treatment option for
late-stage glaucoma when conventional treatments have failed
to arrest progression towards blindness, given that monthly intra-
vitreal injections of anti-VEGF agents have become routine clinical
care in the treatment of neovascular age-related macular
degeneration.
In summary, we have demonstrated that human MSCs are able
to enhance the survival of RGCs under the harsh conditions
of in vitro culture following complete axotomy, as observed
RGC neuroprotection by MSCs and PDGF Brain 2013: Page 15 of 17 | 15
previously for rat MSCs (Bull et al., 2011). Among many factors
secreted by MSCs that appear to promote RGC survival, PDGF
family members conferred a particularly strong neuroprotective
effect both in vitro and in vivo, which appears to be dependent
on PI3 kinase signalling. Future work will evaluate the translational
potential of local MSC transplantation for the treatment of glau-
coma, alongside targeting PDGF signalling pathways through stem
cell-independent methods, such as through drug development.
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 Figure S1. Flow cytometric analyses of rat mesenchymal stem cells. Green fluorescent 
protein (GFP)-expression rat mesenchymal stem cells (rMSCs) were dissociated and analysed for 
GFP expression and expression of cell surface receptors associated with mesenchymal or 
hematopoietic lineage as indicated in Methods.  Cells were gated by GFP fluorescence (A), 
Alexa Fluor-647 fluorescence (B), PE fluorescence (C), or Alexa Fluor-633 fluorescence (all 
others).  Negative controls (dotted lines) included rMSCs from wild type animals (A) or rMSCs 
in which the primary antibody was omitted from the immunofluorescence protocol (B-I). 
 

